Redeye returns with adjusted estimates and a new Base Case following the Q2’21 report. According to us, the shellshock -30% share price drop was an overreaction, and the new levels should prove favorable for investors buying into the long-term story.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source